ABVC (ABVC BioPharma) Tariff Resilience Score: 7/10 (As of Jun. 26, 2026)


ABVC ABVC BioPharma Inc ABVC
17 GF Score
Price $1.46
GF Value $0.87
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is ABVC BioPharma Tariff Resilience Score?

ABVC BioPharma ABVC +1.39% 17 Tariff Resilience Score is 7 as of Jun. 26, 2026. GuruFocus rates ABVC with a GF Score™ of 17/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,378 Biotechnology companies, ABVC BioPharma ranks better than 90.42% on this metric.

ABVC BioPharma has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

ABVC BioPharma has Biopharma company with some international supply chain dependencies. Manufacturing and sales are primarily domestic, reducing tariff impact. Has alternative suppliers and pricing power to mitigate risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes ABVC BioPharma might have Highly Resilient.

ABVC BioPharma  (NAS:ABVC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

ABVC BioPharma Tariff Resilience Score Related Terms

ABVC vs GRDX, INMB, ALGS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, ABVC BioPharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ABVC BioPharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABVC BioPharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where ABVC BioPharma's Tariff Resilience Score falls into.


ABVC
17GF Score
ABVC BioPharma Inc ABVC
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
ABVC BioPharma (ABVC) has a Tariff Resilience Score of 7 as of Jun. 26, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, ABVC BioPharma ranks #132 out of 1378 companies in the Biotechnology industry, placing it in the top 9.6%.
Is ABVC BioPharma's Tariff Resilience Score too high?
ABVC BioPharma's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. ABVC BioPharma's value of 7 is 75% above this industry median. Based on the distribution chart, ABVC BioPharma ranks #132 out of 1378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's Tariff Resilience Score compare to GRDX and INMB?
According to the Biotechnology industry distribution chart, ABVC BioPharma ranks #132 out of 1378 companies for Tariff Resilience Score. This places ABVC BioPharma in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. ABVC BioPharma's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABVC BioPharma's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABVC BioPharma's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.46 — trading 67.8% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current Tariff Resilience Score is 7 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABVC BioPharma (ABVC) Overvalued in 2026?

Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued. The current stock price of $1.46 is trading 67.8% above its estimated GF Value™ of $0.87. GuruFocus considers ABVC BioPharma to be Significantly Overvalued.

Key valuation signals for ABVC:

  • Tariff Resilience Score: 7
  • GF Value™: $0.87 vs. price of $1.46 (67.8% above fair value)
  • GF Score™: 17/100 with 1 warning sign
  • Industry Position: 75% above the Biotechnology median (#132 of 1378)

No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ABVC BioPharma Business Description

Address 44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score

Get the complete analysis for ABVC

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.46
Price
$0.87
GF Value